Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · May 27, 2009

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• • Conditions for patient eligibility
• Inclusion criteria:
• • Patients must be female.
• • Patients must be 18 years of age or older.
• • Patients with stage IIA, IIB, IIIA (T1-3 and N1-2) breast cancer. Clinical N0 accepted if biopsy proven node disease.
• • Patients that have biopsy proven positive axillary disease made by core needle biopsy or fine needle aspiration .
• • Patients that accept to undergo neoadjuvant chemotherapy; patients are eligible until the day of surgery.
• • Patients with bilateral breast cancer are eligible. Sentinel node biopsy is allowed on the contralateral breast if there is no disease in the axilla prior to chemotherapy.
• • Patients that understand, accept and have signed the approved consent form.
• Exclusion Criteria:
• • Patients with inflammatory breast cancer.
• • Patient with stage IIIB, IIIC or IV breast cancer (T4 and N3) Patients with clinical N3 disease are excluded.
• • Patients that have had previous axillary dissection or an axillary sentinel node biopsy; (patients that have had excisional biopsy or ipsilateral tumorectomy are eligible).
• • Patients that have had previous radiotherapy to the axillary nodes
• • Patients that have had mammary reduction
• • Patients that are medically unfit to receive chemotherapy, as evaluated by the treating physician.
• • If the injection of blue dye is planned, patients with hypersensitivity or allergy to isosulfan blue, Patent blue or methylene blue or radiocolloid dye are ineligible.
• • Patients who are pregnant or breast feeding .
• • Psychiatric or addictive disorders or other conditions that preclude the patient from meeting the study requirements.